Eagle Pharmaceuticals, Inc. (EGRX)
Largest Insider Buys in Sector
EGRX Stock Price History Chart
EGRX Stock Performance
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for …
Insider Activity of Eagle Pharmaceuticals, Inc.
Over the last 12 months, insiders at Eagle Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Eagle Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eagle Pharmaceuticals, Inc. have bought $0 and sold $1.02M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 350 shares for transaction amount of $19,406 was made by Meyers Pete A. (Chief Financial Officer) on 2017‑08‑16.
List of Insider Buy and Sell Transactions, Eagle Pharmaceuticals, Inc.
| 2023-11-02 | Sale | CEO | 10,694 0.0805% | $13.87 | $148,326 | -66.22% | ||
| 2023-11-01 | Sale | CEO | 10,925 0.0836% | $13.82 | $150,984 | -65.76% | ||
| 2023-10-03 | Sale | CEO | 10,734 0.0786% | $14.46 | $155,174 | -64.53% | ||
| 2023-10-02 | Sale | CEO | 9,511 0.0733% | $15.23 | $144,853 | -66.65% | ||
| 2023-05-16 | Sale | CEO | 15,000 0.1151% | $19.98 | $299,700 | -55.02% | ||
| 2023-05-15 | Sale | CEO | 15,000 0.1151% | $21.07 | $315,992 | -57.19% | ||
| 2023-05-12 | Sale | CEO | 15,000 0.1131% | $20.27 | $304,014 | -54.20% | ||
| 2023-05-11 | Sale | CEO | 15,000 0.1135% | $20.71 | $310,650 | -54.64% | ||
| 2022-09-06 | Sale | 6,800 0.0512% | $30.99 | $210,732 | -10.69% | |||
| 2019-10-25 | Sale | director | 15,437 0.1119% | $63.57 | $981,302 | -23.33% | ||
| 2019-10-24 | Sale | director | 1,494 0.0109% | $62.53 | $93,413 | -21.42% | ||
| 2019-10-23 | Sale | director | 200 0.0015% | $62.58 | $12,516 | -21.06% | ||
| 2019-10-22 | Sale | director | 6,567 0.048% | $62.68 | $411,618 | -21.14% | ||
| 2019-10-21 | Sale | director | 3,849 0.0281% | $62.56 | $240,791 | -20.90% | ||
| 2019-10-18 | Sale | director | 1,600 0.0118% | $62.61 | $100,174 | -19.82% | ||
| 2019-10-17 | Sale | director | 13,842 0.1007% | $62.58 | $866,196 | -20.80% | ||
| 2019-10-16 | Sale | director | 102 0.0007% | $62.50 | $6,375 | -19.97% | ||
| 2019-10-15 | Sale | director | 3,909 0.0287% | $62.63 | $244,836 | -19.71% | ||
| 2019-10-11 | Sale | director | 16,300 0.1192% | $60.39 | $984,419 | -16.19% | ||
| 2019-10-10 | Sale | director | 7,829 0.0569% | $60.16 | $471,002 | -16.16% |
Insider Historical Profitability
| Moorin Jay | 4770828 36.8171% | $0.95 | 1 | 0 | <0.0001% | |
| SCHREIBER ALAIN | 4770828 36.8171% | $0.95 | 1 | 0 | <0.0001% | |
| ProQuest Associates IV LLC | 10 percent owner | 4770828 36.8171% | $0.95 | 1 | 0 | <0.0001% |
| Braunstein Douglas L | director | 811777 6.2646% | $0.95 | 1 | 2 | +18.31% |
| Edlin Richard A. | 22600 0.1744% | $0.95 | 1 | 1 | <0.0001% |
Institutional Investor Ownership
| Nantahala Capital Management Llc | $6.6M | 9.69 | 1.26M | New | +$6.6M | 0.31 | |
| Aigh Capital Management Llc | $6.22M | 9.14 | 1.19M | New | +$6.22M | 3.56 | |
| BlackRock | $4.7M | 6.91 | 897,806 | -8.84% | -$456,414.63 | <0.0001 | |
| AQR Capital | $4.61M | 6.77 | 879,073 | +78.07% | +$2.02M | 0.01 | |
| The Vanguard Group | $3.36M | 4.93 | 640,754 | +0.41% | +$13,781.20 | <0.0001 |